Stem Cell Cancer And Regenerative Medicine Research Inc

Organization Overview

Stem Cell Cancer And Regenerative Medicine Research Inc is located in Boynton Beach, FL. The organization was established in 2007. According to its NTEE Classification (H90) the organization is classified as: Medical Disciplines Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Stem Cell Cancer And Regenerative Medicine Research Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 12/2021, Stem Cell Cancer And Regenerative Medicine Research Inc generated $240.8k in total revenue. This organization has experienced exceptional growth, as over the past 7 years, it has increased revenue by an average of 53.3% each year . All expenses for the organization totaled $275.8k during the year ending 12/2021. While expenses have increased by 7.4% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2021

Describe the Organization's Mission:

Part 3 - Line 1

SEE SCHEDULE O FOR DESCRIPTION THE ORGANIZATION IS TO BE OPERATED FOR SCIENTIFIC AND EDUCATIONAL PURPOSES TO CONDUCT RESEARCH TO UNCOVER THE MOLECULAR BASIS OF CANCER AND DEGENERATIVE DISEASES WITH THE EMPHASIS ON CANCER INCLUDING MULTIPLE MYELOMA AND OTHER CHRONIC DISEASES INCLUDING FRAILTY..

Describe the Organization's Program Activity:

Part 3 - Line 4a

IN MAY 2008 THE ORGANIZATION STARTED A COLLABORATION WITH SCIENTISTS AT WAKE FOREST UNIVERSITY WHO HAVE DEVELOPED A PROTOCOL FOR USING GRANULOCYTES FOR TREATING SOLID TUMORS. THE PROTOCOL WAS MODIFIED FOR IMPLEMENTATION AND INVESTIGATIONAL NEW DRUG APPROVAL WAS OBTAINED IN OCTOBER 2008 FOR A PHASE I/II CLINICAL TRIAL FOR 29 PATIENTS. WESTERN INSTITUTIONAL REVIEW BOARD APPROVAL WAS OBTAINED IN NOVEMEBER 2008. THROUGH 2021, 17 PATIENTS HAVE BEEN TREATED AND 244 DONORS HAVE BEEN EVALUATED.


YOUNG BLOOD CLINICAL STUDY UNDER FOOD AND DRUG ADMINISTRATION APPROVAL EVALUATING THE SAFETY AND EFFICACY OF FRESH FROZEN PLASMA (GMFFP) FROM YOUNG HEALTHY DONORS AGES 18 TO 35, WHO HAVE GRANULOCYTE - COLONY STIMULATING FACTOR (G-CSF) TO AMELIORATE FRAILTY AND ENHANCE THE IMMUNE RISK PROFILE IN OLDER INDIVIUALS.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$0
Related organizations$0
Government grants $0
All other contributions, gifts, grants, and similar amounts not included above$240,472
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$240,472
Total Program Service Revenue$0
Investment income $369
Tax Exempt Bond Proceeds $0
Royalties $0
Net Rental Income $0
Net Gain/Loss on Asset Sales $0
Net Income from Fundraising Events $0
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $240,841

Grants Recieved

Over the last fiscal year, we have identified 2 grants that Stem Cell Cancer And Regenerative Medicine Research Inc has recieved totaling $100,020.

Awarding OrganizationAmount
Collis Foundation

Providence, RI

PURPOSE: GENERAL OPERATING SUPPORT

$100,000
Amazonsmile Foundation

Seattle, WA

PURPOSE: GENERAL SUPPORT

$20
View Grant Recipient Profile

Create an account to unlock the data you need.

or